Hope I'm not getting ahead of myself, but I think this is another "signal" that Leo expects to have "the best path forward for the Company" through a partnership in relatively short order...

"To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018."

So with all that is in our pipeline and the limited funds we have, Leo is planning on moving the topical/dermatological indications forward, already by Q2? I think the only way this is possible is if we have already secured a partnership. To me this really suggests Leo expects a path forward before the end of Q2.

Things are going to move here in short order. Hold onto your hats.